fda bpc-157 not approved human use statement An advisory committee voted Thursday to remove compounding restrictions on four peptides despite little evidence the products are safe or effective for medical use. In a series of 8-6 votes (with FDA Discusses Peptide Bulk Substances

A 5-residue peptide is substantially cheaper to synthesize cleanly than a 40-residue one

However: all potency data is from animal models

What long-term safety data are available for BPC-157

A commenter recommended that CMS urge QCDRs and qualified registries not to use this extended timeline to delay, but rather to complete any necessary modifications by the earliest practicable convenience

Advantage: Convenient, familiar, non-invasive Challenge: Peptides face proteolytic degradation in the stomach and small intestine Bioavailability: Estimated at approximately 38% based on comparative pharmacology (see below) Transdermal (Patch) Some researchers have explored transdermal patches to deliver peptides: Advantage: Avoids first-pass metabolism and GI degradation Challenge: Intact skin is a strong barrier to peptide penetration Feasibility: Not commonly available commercially